세계의 혈장 유도체 시장 : 유형별, 프로세스별, 용도별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Blood Plasma Derivatives Market is accounted for $56.71 billion in 2025 and is expected to reach $115.52 billion by 2032 growing at a CAGR of 10.7% during the forecast period. Human plasma, the liquid component of blood, is the source of specialized medicinal products known as blood plasma derivatives. Essential proteins like albumin, immunoglobulins, clotting factors, and alpha-1 antitrypsin are among these derivatives and are frequently used to treat a variety of illnesses. Immunodeficiencies, hemophilia, and neurological conditions like Guillain-Barre syndrome are all treated with their help. Fractionation, a technique used to isolate and purify particular proteins for medical applications, yields plasma derivatives.

According to the World Federation of Hemophilia (WFH), hemophilia affects approximately 1 in 10,000 people globally.

Market Dynamics:

Driver:

Increasing number of elderly people

A major factor in the rising demand for therapies derived from plasma is the aging population. The elderly are significant users of plasma derivatives because they are more susceptible to diseases like coagulation problems, chronic liver disease, and immunological deficiencies. Approximately 1.6 billion people, or one in six people worldwide, will be over 65 by 2050, according to UN estimates. Additionally, the risk of infections, cardiovascular conditions, and autoimmune diseases increases with age; many of these conditions are treated with plasma proteins such as albumin and immunoglobulins.

Restraint:

Exorbitant expenses for production and processing

The complicated and time-consuming plasma fractionation process makes the production of therapies derived from plasma extremely costly. Plasma collection and final product release can take seven to twelve months, which results in high operating costs. For plasma proteins to remain stable and effective, plasma fractionation necessitates specialized equipment, rigorous quality control testing, and a sizable storage infrastructure. Furthermore, the total cost of production is raised by the requirement for several liters of plasma to generate a small amount of the finished product. For instance, to make enough Intravenous Immunoglobulin (IVIG) to treat one patient for a year, about 130 plasma donations are needed.

Opportunity:

Growing interest in immunoglobulin and plasma treatments

Intravenous immunoglobulins (IVIG) and subcutaneous immunoglobulins (SCIG) are in high demand due to the increasing incidence of immune deficiencies, neurological conditions, and autoimmune diseases. Long-term immunoglobulin therapy is necessary for conditions like Kawasaki disease, chronic inflammatory demyelinating polyneuropathy (CIDP), and primary immunodeficiency disorders (PIDD). Industry estimates indicate that the demand for IVIG has been rising globally at a rate of more than 8% per year, which has created significant growth prospects for the market. Moreover, prospects for the market are further enhanced by the extension of plasma-derived immunoglobulin treatment indications into conditions like sepsis, multiple sclerosis, and Alzheimer's disease.

Threat:

Lack of plasma donations and limitations on supply

The worldwide supply of plasma is largely reliant on donor participation, which varies depending on socioeconomic factors, regulatory limitations, and public attitudes regarding plasma donation. Policy changes and donor compensation ethical discussions could cause disruptions for nations like the US that depend on compensated plasma donation models. Additionally, the COVID-19 pandemic brought to light the vulnerability of plasma collection, as notable drops in donations resulted in immunoglobulin and clotting factor shortages.

Covid-19 Impact:

The COVID-19 pandemic had a major effect on the market for blood plasma derivatives because it caused delays in manufacturing, disruptions in plasma collection, and an increase in demand for immunoglobulins. Lockdowns and social distancing policies caused plasma donations to drop, particularly in important markets like the US and Europe, which resulted in a shortage of vital therapies derived from plasma. Furthermore, the supply chain for other plasma-derived products was also impacted by the brief shift in industry focus caused by the explosion in research on convalescent plasma therapy for COVID-19 patients.

The Immunoglobulin segment is expected to be the largest during the forecast period

The Immunoglobulin segment is expected to account for the largest market share during the forecast period, motivated by its extensive application in the treatment of autoimmune diseases, primary and secondary immunodeficiency's, and neurological disorders like Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP). The demand for immunoglobulin products has been driven by the growing number of elderly people, the increasing prevalence of immunodeficiency diseases, and the growing knowledge of plasma-derived treatments. Furthermore, improvements in immunoglobulin formulations for intravenous (IVIG) and subcutaneous (SCIG) administration have enhanced patient convenience and treatment compliance.

The Chromatography segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Chromatography segment is predicted to witness the highest growth rate, motivated by its exceptional efficiency, purity, and precision in plasma protein separation. Chromatography is becoming more and more popular for producing immunoglobulins, albumin, and coagulation factors because it provides superior yield and specificity compared to conventional techniques like cold ethanol fractionation. Its quick adoption is being fueled by the rising demand for high-purity plasma-derived treatments, improvements in affinity and ion-exchange chromatography, and rising investments in biopharmaceutical research. Moreover, the market growth of chromatography-based purification is further enhanced by regulatory bodies' preference for it because of its superior pathogen removal capabilities.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by a robust presence of major market players, high plasma donation rates, and sophisticated healthcare infrastructure. Because of its well-established plasma donation facilities and advantageous reimbursement policies, the United States leads the region and contributes significantly to global plasma collection. The market is growing due to the rising incidence of neurological diseases, hemophilia, and immune disorders, as well as increased awareness of therapies derived from plasma. Additionally, North America's dominant market position is also a result of the FDA's strong regulatory support, continuous research into plasma fractionation technologies, and widespread use of immunoglobulin treatments.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by the growing prevalence of immunodeficiency disorders, growing awareness of plasma-derived therapies, and rising healthcare costs. Government support for biologics and plasma fractionation, growing plasma collection programs, and better healthcare infrastructure are all contributing to the rapid expansion of nations like China, India, and Japan. The market is growing as a result of rising demand for coagulation factors and immunoglobulins, as well as investments in sophisticated purification technologies and growing pharmaceutical manufacturing capacities.

Key players in the market

Some of the key players in Blood Plasma Derivatives Market include Bayer AG, Fusion Health Care Pvt. Ltd., Grifols, S.A., Takeda Pharmaceutical Company, Sanofi, CSL Limited, LFB S.A., Baxter International Inc., Syntegon, Green Cross Corporation, Octapharma AG, Biotest AG, Kedrion Biopharma, Inc., SK Plasma Co., Ltd. and Intas Pharmaceuticals Ltd.

Key Developments:

In February 2025, Sanofi and CD&R have signed the share purchase agreement for the sale of a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). The terms of the transaction remain unchanged from those previously announced and closing is expected in the second quarter of 2025 at the earliest.

In January 2025, Bayer announced that the company has signed a new exclusive distribution agreement with UK-based Ecospray to market a biological liquid nematicide sourced from garlic. The product presents a biological alternative to traditional synthetic chemical nematicides in vegetable and potato crops, and will be marketed in the European Union under the new name Velsinum(TM).

In June 2024, Takeda announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.

Types Covered:

• Albumin
• Factor VIII
• Factor IX
• Immunoglobulin
• Hyperimmune Globulin
• Other Types

Processes Covered:

• Cold Ethanol Fractionation
• Heat Treatment
• Chromatography

Applications Covered:

• Hemophilia
• Hypogammaglobulinemia
• Immunodeficiency Diseases
• Von Willebrand'S Disease
• Other Applications

End Users Covered:

• Hospitals
• Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Blood Plasma Derivatives Market, By Type

• 5.1 Introduction
• 5.2 Albumin
• 5.3 Factor VIII
• 5.4 Factor IX
• 5.5 Immunoglobulin
• 5.6 Hyperimmune Globulin
• 5.7 Other Types

6 Global Blood Plasma Derivatives Market, By Process

• 6.1 Introduction
• 6.2 Cold Ethanol Fractionation
• 6.3 Heat Treatment
• 6.4 Chromatography

7 Global Blood Plasma Derivatives Market, By Application

• 7.1 Introduction
• 7.2 Hemophilia
• 7.3 Hypogammaglobulinemia
• 7.4 Immunodeficiency Diseases
• 7.5 Von Willebrand'S Disease
• 7.6 Other Applications

8 Global Blood Plasma Derivatives Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Other End Users

9 Global Blood Plasma Derivatives Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Bayer AG
• 11.2 Fusion Health Care Pvt. Ltd.
• 11.3 Grifols, S.A.
• 11.4 Takeda Pharmaceutical Company
• 11.5 Sanofi
• 11.6 CSL Limited
• 11.7 LFB S.A.
• 11.8 Baxter International Inc.
• 11.9 Syntegon
• 11.10 Green Cross Corporation
• 11.11 Octapharma AG
• 11.12 Biotest AG
• 11.13 Kedrion Biopharma, Inc.
• 11.14 SK Plasma Co., Ltd.
• 11.15 Intas Pharmaceuticals Ltd.